Summary Liquid biopsy using circulating tumor DNA (ctDNA) is increasingly used for cancer profiling and monitoring, but blood-based analysis may not capture tumor heterogeneity across anatomical compartments. We evaluated cell-free DNA from cerebrospinal (n = 7), pleural (n = 11), pericardial (n = 1), and ascitic (n =...
A. Shreenivas, S. Limaye, M. Cristofanilli et al.· iScience· 0 citations
Current professional guidance supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-b...
H. Al-Shamsi, S. Rafii, S. Tirmazy et al.· OncoTargets and Therapy· 0 citations
A narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured.
Farhood Farahnak, W. El-Deiry, Yves A. Lussier et al.· JCO Global Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.